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ABSTRACT
Objective: To evaluate the cost-effectiveness of fonda-
parinux relative to enoxaparin as prophylaxis against venous
thromboembolism (VTE) in patients undergoing hip fracture
surgery.
Methods: A decision analysis model was created to simulate
the impact of fondaparinux 2.5 mg once daily relative to
enoxaparin 30 mg twice daily on patient outcomes and costs
over various time points up to 5 years after surgery. Proba-
bilities for the analysis were estimated for a hypothetical
cohort of 1000 patients undergoing hip fracture surgery in
the United States receiving either fondaparinux or enoxa-
parin according to comparative trial results. Resource use
and costs (2003 dollars) were obtained from large health-
care databases. Outcome measures were rates of sympto-
matic VTE events, health-care costs, and incremental cost-
effectiveness ratios.
Results: Fondaparinux is estimated to prevent an additional
30 VTE events (per 1000 patients) at 3 months compared
with enoxaparin, producing savings of $103 at discharge,
$290 over 1 month, $361 over 3 months, and $466 over
5 years. The results remain robust to clinically plausible var-
iation in input parameters and assumptions.
Conclusions: Fondaparinux improves outcomes and is cost-
saving over a broad range of assumptions compared with
enoxaparin for prophylaxis of VTE after hip fracture
surgery.
Keywords: cost-effectiveness, fondaparinux, hip fracture
surgery, venous thromboembolism.
Introduction
Venous thromboembolism (VTE), encompassing deep-
vein thrombosis (DVT) and pulmonary embolism (PE),
remains an important cause of morbidity and mortal-
ity among patients undergoing hip fracture surgery [1].
Without prophylaxis, the incidence of DVT
approaches 50% while fatal PE occurs in up to 12% of
patients [1]. Because of this, thromboprophylaxis is
routinely used in the majority of patients. Fonda-
parinux, a novel synthetic antithrombotic has recently
been approved in the United States for prevention of
VTE in patients undergoing hip fracture surgery. In a
pivotal trial known as PENTHIFRA (PENTasaccha-
ride in HIp FRActure surgery), fondaparinux, when
administered for 7 to 10 days, was signiﬁcantly more
effective than the widely used low-molecular-weight
heparin enoxaparin, with VTE reduced from 19.3%
(119/624) to 8.3% (52/626), representing a relative
risk reduction of 58% (P < 0.001), with no difference
in clinically relevant bleeding [2].
In 2002, 315,000 hip fractures occurred in the
United States [3], a ﬁgure which is expected to
increase, in persons aged 50 years or above, by 70%
over the next 40 years [4]. This increase, explained pri-
marily by the aging of the population, has resulted in
more attention being placed on the economic conse-
quences of hip fracture surgery and its associated treat-
ments [5]. The introduction of new prophylactic
therapies, such as fondaparinux, has implications for
hospital and pharmacy budgets and as a result, the
economic costs and beneﬁts need to be examined.
Based on guidelines for assessing outcomes of
prophylaxis after major orthopedic surgery [6], an eco-
nomic model has been developed to compare the cost-
effectiveness of fondaparinux with enoxaparin, for
patients undergoing major orthopedic surgery in the
United States, including hip fracture surgery [7]. Using
a 5-year decision analysis model, the outcomes and
costs of VTE-related care were assessed. In the main
analysis, for a hypothetical cohort of patients under-
going total hip replacement, total knee replacement or
hip fracture surgery, fondaparinux was cost-saving
compared with enoxaparin over a broad range of
assumptions evaluated [7]. The greatest savings were
demonstrated in patients undergoing hip fracture
surgery.
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In view of the cost implications associated with the
high VTE risk after hip fracture surgery, we used the
same economic model to concentrate on a cohort of
patients undergoing hip fracture surgery and deter-
mine the cost-effectiveness of fondaparinux from the
perspective of the US health-care payer.
Methods
Decision Model
A full description of the economic model has been pub-
lished [7], with the main outcomes for each time
period shown in Figure 1. Brieﬂy, the decision analytic
model enables translation of clinical trial end points
(venographic DVT) into end points relevant to routine
practice (clinical DVT and PE), and extrapolates the
economic consequences beyond the time horizon of
clinical trials. In particular, shorter postoperative hos-
pital admissions mean that a greater proportion of
VTE events occur after hospital discharge. The model
relies on several key assumptions. First, hospitalized
patients may develop a clinically apparent (sympto-
matic) or silent (asymptomatic) thrombotic event. In
line with daily clinical practice, detection of DVT or
PE is based on symptomatic presentation, which is
subsequently conﬁrmed by objective testing. Second, it
accounts for those patients who may be incorrectly
suspected of having a DVT or PE. Third, patients with
conﬁrmed VTE who undergo treatment are assumed to
remain at risk of long-term complications (recurrent
VTE or post-thrombotic syndrome [PTS]). Finally,
patients with undetected and untreated DVT are
assumed to be at risk of PTS. In addition, the model
considers the risk of death and reﬂects the risk of
major bleeding, fatal or nonfatal, during either proph-
ylaxis or treatment of a VTE event.
Two distinct periods exist in the model: an acute
phase, beginning with surgery and ending at 90 days
(3 months); and a chronic phase, beginning on day 91
and ending 5 years after surgery. In the acute phase,
“early” thrombi are deﬁned as those developing dur-
ing the period of hospitalization, and “late” thrombi
as those developing between hospital discharges and
day 30. Patients with early or late thrombi can present
with clinical VTE before day 90 or can remain asymp-
tomatic with future consequences. During the chronic
phase patients are assumed to be at risk of long-term
complications (recurrences, PTS) based on outcomes
during the acute phase, even if they had subclinical
events during the acute phase.
Figure 1 The cost-effectiveness decision model. A decision analytic model showing the range of clinical alternatives and outcomes that may occur in the
prevention of venous thromboembolism (VTE) after hip fracture surgery. The circles represent chance nodes for a particular event. Thrombi (early or
late) that would have been detected on bilateral systematic venography can remain as asymptomatic thrombi or develop into symptomatic VTE. Patients
with detected (and conﬁrmed) VTE are assumed to undergo treatment and remain at risk of long-term complications (Box 1). Patients with undetected
(silent, or asymptomatic) and hence untreated VTE are also assumed to be at risk of long-term complications (Box 2). Suspected but not conﬁrmed deep-
vein thrombosis or pulmonary embolism, and major bleeding related to treatment of VTE, are included in the model but not represented on this ﬁgure.
*Long-term complications include VTE recurrences and post-thrombotic syndrome.
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Economic Analysis
The model compares the costs and outcomes of 7 days
of fondaparinux 2.5 mg (Arixtra, GlaxoSmithKline,
London,  UK)  administered  once  daily  with  7 days
of enoxaparin 30 mg (Lovenox, Aventis Pharma,
Bridgewater, NJ, the United States) administered twice
daily in patients undergoing hip fracture surgery.
Enoxaparin is used as the comparator because it was
the reference therapy used in the PENTHIFRA study
[2], and is a standard of care recommended by the
American College of Chest Physicians [1]. It also has
been found to be cost-effective in numerous analyses,
compared with either warfarin [8–11] or unfraction-
ated heparin [12]. The balance between costs and
effects is assessed by computing the incremental cost-
effectiveness ratios, being the costs per symptomatic
VTE event avoided, at various time points. The time
horizon of the analysis includes hospital discharge, 30
and 90 days, and extends out to 5 years after surgery.
The main outcome data are presented at discharge and
at 90 days (3 months), because this is the period when
the majority of thrombi manifest clinically.
The analysis is conducted on a hypothetical cohort
of 1000 patients undergoing hip fracture surgery in the
United States using the recommended dosing regimen
of enoxaparin of 30 mg twice daily and commenced
postoperatively. In the PENTHIFRA study enoxaparin
was administered as 40 mg once daily preoperatively.
It is assumed that the mean length of hospital stay is
7 days for patients undergoing hip fracture surgery,
which is consistent with national statistics [3].
Event Probabilities
Because of a paucity of various outcomes for patients
undergoing hip fracture surgery, data were extrapo-
lated from patients undergoing hip replacement when
information was not available. In particular, using data
from the PENTHIFRA study and the more recent
PENTHIFRA-Plus study, which evaluated the use of
fondaparinux for up to 4 weeks after hip fracture sur-
gery, the probability of symptomatic VTE events in
patients undergoing hip fracture surgery was estimated
to be 2.2 times that after hip replacement [2,13]. In the
previous analysis [7], a more conservative hip fracture
multiplier of 1.7 was used, which is now updated
based on more recently available evidence.
Enoxaparin. Early thrombi rates were based on
results from the PENTHIFRA study whereas the
occurrence of symptomatic VTE at 90 days was esti-
mated from a cohort study and randomized trial of
patients undergoing total hip replacement [14,15]. The
risk of late thrombi was estimated from a study of total
hip replacement patients who had negative ﬁndings on
venography at the time of hospital discharge [16],
applying the above-mentioned multiplier (2.2) to
extrapolate to a hip fracture population. Rates of
symptomatic VTE occurring from late thrombi were
estimated from a study by Hull and colleagues [17].
The temporal distribution of symptomatic VTE events
after hip fracture surgery is similar to that after hip
replacement [18] and was extrapolated from a large
cohort study by White and colleagues [19] (Table 1).
Fondaparinux. The probabilities of early thrombi
were based on the venographic results from the PEN-
THIFRA study [2], which showed the relative risk of
early thrombi (venographic DVT) relative to enoxa-
parin to be 0.58. The probabilities of clinical VTE
were estimated by assuming that the ratios of veno-
graphic DVT that become symptomatic were similar to
that for enoxaparin. Despite a lack of conclusive infor-
mation concerning the occurrence of late thrombi and
subsequent clinical events, it is assumed that there was
no difference compared with enoxaparin.
Bleeding risk. The risk of prophylaxis-related major
bleeding was based on the observed rates seen in the
PENTHIFRA study [2]. The risk of major bleeding
related to the treatment of clinical VTE was estimated
from pooled data of randomized clinical trials involv-
ing heparin, and/or warfarin where there was at least
3 months follow-up [20–27].
Other  probability  estimates. Rates of suspected but
unconﬁrmed DVT (10%) and PE (2%) were obtained
from the literature and assumed not to differ by type of
prophylaxis received [28]. The risk of recurrent VTE
over 5 years was based on methods described in the
original cost-effectiveness model [7]. Brieﬂy, outcomes
for long-term follow-up study of patients with objec-
tively veriﬁed symptomatic DVT was adjusted for a
hip fracture surgery cohort [29] This estimate was
apportioned between the acute and chronic phases,
with the risk of recurrence assumed to begin immedi-
ately after an initial DVT or PE. Data from VTE treat-
Table 1 Key baseline event probabilities
Event Fondaparinux Enoxaparin Source
Early thrombi* 0.0785 0.1878 [2]
Early clinical DVT† 0.0157 0.0375 [2,14,15,19]
Early clinical PE† 0.0089 0.0212 [2,14,15,19]
Late thrombi‡* 0.1932 0.1932 [16,19]
Late clinical DVT† 0.0251 0.0221 [2,14,15,17]
Late clinical PE† 0.0031 0.0028 [2,14,15,17]
Prophylaxis-related 
major bleeding
0.0217 0.0226 [2]
Recurrent VTE‡ 0.0451 0.0451 [20–27,29,30]
PTS‡
After clinical VTE 0.2800 0.2800 [31]
After subclinical VTE 0.1168 0.1168 [32,33]
*Thrombi refers to DVT detected by systematic venography.
†Cumulative to day 90.
‡Probabilities are presented at 5 years.
Note: Rounding has been applied to some ﬁgures.
DVT, deep-vein thrombosis; PE, pulmonary embolism; PTS, post-thrombotic syn-
drome; VTE, venous thromboembolism.
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ment trials [20–27,30] were used to estimate the risk of
recurrence during the ﬁrst 90 days versus later and
recurrence during the chronic phase was distributed
according to the temporal pattern observed in the
long-term study [29]. The risk of PTS was assumed to
begin at day 91 (chronic phase) and estimates were
made separately depending on the development of clin-
ical or subclinical DVT within 3 months of surgery.
Cumulative risks of PTS after acute DVT were derived
from a long-term outcome study [31]. Because of
inconsistent data concerning the incidence of PTS after
untreated subclinical DVT we used a weighted inci-
dence from two studies (12%) [32,33] reporting the
incidence of PTS among patients developing veno-
graphic DVT that is subsequently treated.
In view of a lack of epidemiological data, the risk of
fatal PE was derived from the PENTHIFRA study
(68.2%) [2]. The risk of death after major bleeding
(0.63%) was derived from the percentage of patients
with major bleeding from four large fondaparinux
orthopedic clinical trials whose bleeding was deemed
to be the cause of death after adjudication [2,34–36].
The probabilities of death from other causes (i.e.,
deaths unrelated to VTE) were estimated from US
National Statistics.
Estimates of Resource Use and Costs
The costs of managing VTE, including the costs of
investigations for suspected VTE events, treatment of
conﬁrmed cases, management of major bleeding, and
the long-term sequelae of VTE were determined from
various sources, as previously described (Table 2) [7].
Patients developing clinical VTE during the initial hos-
pitalization were assumed to require extended stays in
hospital, whereas those developing VTE after dis-
charge are either readmitted or treated at home. The
proportion of patients treated either in the inpatient
and outpatient setting was determined from a claims
database.
Work-up costs for suspected but unconﬁrmed VTE
were based on a previous economic evaluation [12].
In-hospital VTE management costs were derived from
a large multihospital Clinical Pathways Data Base
(CPDB) [37], updated to 2003 prices [38]. VTE events
costs after hospital discharge was derived from a US
health-care claims database [39].
Prophylaxis-related major bleeding costs were sim-
ilarly derived from the CPDB database [37]. Here,
patients undergoing hip fracture surgery were stratiﬁed
according to whether or not they had coded secondary
diagnoses of bleeding with total estimated costs of
inpatient care then compared between groups. Patients
with diagnoses of DVT or PE were excluded from the
sample to minimize the possibility that bleeding was
treatment-related. Minor bleeding costs were not
included in the analysis because of difﬁculty in obtain-
ing precise estimates, and the fact that no difference
was  seen  in  this  outcome  between  fondaparinux
and enoxaparin in the clinical trial. In the absence of
reliable US studies, the costs of treating PTS were
estimated from a Swedish study of long-term
consequences of VTE [40]. Costs were converted from
Swedish kroner using average exchange rates and
updated to 2003 price levels. All costs parameters were
expressed in 2003 US dollars and all costs and effects
beyond 1 year were discounted at 3%.
Sensitivity Analyses
One-way sensitivity analyses were performed at day 90
to test parameter uncertainty. The baseline assump-
tions were varied to examine the effect of credible var-
iations. Where possible the reported 95% conﬁdence
intervals were used, otherwise 50% was added or sub-
tracted to the values.
Results
The number of clinical VTE events prevented and costs
savings at 1 and 3 months when fondaparinux is used
instead of enoxaparin in a cohort of US patients under-
going hip fracture surgery are shown in Table 3. Fon-
daparinux prevents an additional 24.1 clinical events
per 1000 patients at 1 month when used in place of
enoxaparin, and 30 clinical events (18.4 DVT, 11.7
PE) are prevented after 3 months (number needed to
treat [NNT] = 33). In addition, 7.9 deaths from PE
(reduced from 15.9 to 8.0 per 1000 patients) will be
prevented after 3 months. The reduction in VTE events
Table 2 Costs of individual procedures and events for patients
undergoing hip fracture surgery
Variable Event cost ($) Source
Cost of prophylaxis* [44]
Fondaparinux 265
Enoxaparin 242
Cost of treating conﬁrmed
DVT
In-hospital 16,426 [12,37]
Post-discharge 11,210 [12]
PE
In-hospital 12,361 [12,37]
Post-discharge 12,969 [12]
Costs of excluding [12]
Suspected but unconﬁrmed DVT 756
Suspected but unconﬁrmed PE 957
Cost of adverse events
Major bleeding 4,788 [G. Oster, 
pers. comm.]
Costs of long-term complications
Acute PTS (1st quarter)† 2,133 [31–33]
Chronic PTS (subsequent quarters)† 355 [31–33]
*Prophylaxis costs included the acquisition cost of each drug (fondaparinux $34.8/
day, enoxaparin $30.8/day), as well as the administration ($0.65/day) and monitoring
costs ($16.8 per patient) of each therapy for 7 days.
†Includes cost of treating varicose veins, venous ulcer, chronic venous insufﬁciency,
and cellulitis. First quarter is from days 1–90; subsequent quarters yearly.
DVT, deep-vein thrombosis; PE, pulmonary embolism; PTS, post-thrombotic
syndrome.
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continue to increase over the 5-year period (Data not
shown). Savings per patient with the use of fonda-
parinux are: $103 at hospital discharge, $290 1 month
after surgery, and $361 3 months after surgery. When
long-term consequences of clinical events are included,
the economic beneﬁts increase with savings of $387 at
year 1 and $466 at year 5 (Table 4 , Fig. 2). At all time
points the greatest cost savings with using fonda-
parinux are seen in reduced requirement for treatment
for clinical VTE events, exceeding the costs of proph-
ylaxis or any adverse events (Fig. 3).
Sensitivity Analysis
The results of the one-way sensitivity analyses at day
90 are illustrated in Table 5. The results are generally
robust to plausible changes in all values tested. Fon-
daparinux remains cost-saving in all assumptions, even
with wide variations in the overall main variables.
Discussion
Patients  who  undergo  hip  fracture  surgery  are  at
the highest risk of VTE. For patients receiving low-
molecular weight heparin, fatal PE occurs in up to 2%
of patients [41]. In the PENTHIFRA study, the syn-
thetic factor Xa inhibitor fondaparinux was signiﬁ-
cantly more effective at reducing VTE than enoxaparin
after hip fracture surgery [2]. This economic analysis
suggests that in addition to its clinical beneﬁts, proph-
ylaxis of VTE with fondaparinux is cost-saving com-
pared with enoxaparin when administered to a cohort
population of US patients undergoing hip fracture sur-
gery. Cost savings of $103 per patient are seen during
hospitalization, which increases after hospital dis-
charge.
The economic model developed for this analysis is
dynamic, in that outcomes can be presented at differ-
ent time points and assessed for different populations
of patients undergoing major orthopedic surgery. Here
we have concentrated on a hip fracture surgery popu-
lation and used a trial-based analysis to maintain trial
validity and reduce uncertainties concerning outcomes.
The majority of cost savings seen with use of fonda-
parinux are due to the reduced number of clinical VTE
events requiring treatment. In particular, each PE or
DVT event after hip fracture surgery requires an
Table 3 Expected outcomes and costs at days 30 and 90*
Variable Fondaparinux Enoxaparin
Difference
(enoxaparin minus fondaparinux)
Outcomes (per 1000 patients)
Up to day 30
Clinical VTE 32.3 56.4 24.1
Major bleeding 19.3 19.0 −0.3
Fatal PE 5.6 11.8 6.2
Up to day 90
Clinical VTE 51.0 81.1 30.1
Major bleeding 19.3 19.0 −0.3
Fatal PE 8.0 15.9 7.9
Costs ($) (per patient)
Up to day 30
Prophylaxis 265 242 −23
Clinical VTE events 395 706 312
Major bleeding 104 108 4
Others† 54 51 −3
Total 818 1107 290
Up to day 90
Prophylaxis 265 242 −23
Clinical VTE events 610 993 383
Major bleeding 110 117 −7
Others† 74 68 −6
Total 1059 1420 361
*Assumes patients receive 7 days administration of therapy in hospital.
†Includes costs of suspected but unconﬁrmed (false-positive) tests for diagnosis of venous thromboembolism, and recurrences.
Note: Figures may not sum because of rounding.
DVT, deep-vein thrombosis; PE, pulmonary embolism; PTS, post-thrombotic syndrome; VTE, venous thromboembolism.
Table 4 Expected cost savings at different time points with use of fondaparinux compared with enoxaparin
Costs per patient at different time points ($)
Discharge Day 30 Day 90 Year 1 Year 5
Fondaparinux 469 818 1059 1117 1301
Enoxaparin 572 1107 1420 1504 1767
Savings with use of fondaparinux 103 290 361 387 466
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additional 7- to 9-day hospitalization for the associ-
ated treatment of each event [37]. Treatment costs for
these events range from $11 to $16,000 per event, with
the range being dependent on the nature of the event
(DVT or PE) and its occurrence either in or out of hos-
pital. The additional costs of prophylaxis, diagnosis of
suspected events and bleeding complications comprise
only a small proportion of overall costs.
In general terms, hospital pharmacies and insurers
have a tendency to bear the cost of prophylaxis
whereas patients accrue some or all of the beneﬁts. At
present, hospital pharmacies and pharmacy beneﬁt
programs of health insurance providers often work
from capitated drug budgets. This practice, termed silo
budgeting, means that paying for expensive drugs
beyond some anticipated level may lead to budget
shortfalls in other areas unless cutbacks are made or
additional funds are identiﬁed [42]. Often a critical
issue in decision-making is whether the “improve-
ment” in a drug therapy warrants an associated
increase in cost. In this regard, the price difference
between fondaparinux and enoxaparin is $23 when
administered for 7 days, a modest increase compared
with the overall cost savings of $103 at hospital dis-
charge. Therefore, with a small incremental price dif-
ference in cost between fondaparinux and enoxaparin,
savings are recouped within 7 days.
As with all economic analyses, several assumptions
were made. The ﬁndings are based on the results of a
single large study [2], in which the efﬁcacy of fonda-
parinux over enoxaparin was clearly demonstrated. In
the PENTHIFRA study [2], enoxaparin was used as
the comparator at a dose of 40 mg once daily, com-
menced preoperatively. In line with current US prac-
tice, this analysis, however, assesses the use of
enoxaparin at a dose of 30 mg twice daily, commenced
postoperatively. We think it is unlikely that the differ-
Figure 2 Distribution of hip fracture surgery costs (per patient) at var-
ious time points.
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Table 5 Sensitivity analysis—cost savings with use of fonda-
parinux compared with enoxaparin per patient at day 90
Test performed Cost savings ($)
Base case 361
Efﬁcacy of fondaparinux vs. enoxaparin varied with
95% CI (Base case 58.2% [95% CI 45.04–71.34%])
276–448
Major bleeding of fondaparinux vs. enoxaparin 
varied ±50%
307–416
Cost of treating conﬁrmed VTE varied ±50% 169–554
Price of fondaparinux vs. enoxaparin varied (low: 
enoxaparin—20%; high: fondaparinux—20%)
318–410
Hip fracture multiplier varied form 1.7–2.7 (Base 
case 2.2)
274–449
Cost of conﬁrming VTE varied ±50% 358–365
Rate of false-positive VTE diagnosis varied ±50% 358–365
Cost of prophylaxis-related bleeding varied ±50% 359–364
CI, conﬁdence interval; VTE, venous thromboembolism.
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ent enoxaparin dosing regimens will have any substan-
tial impact on the efﬁcacy and safety outcomes
demonstrated in this analysis. This is highlighted by
the sensitivity analysis where variations of 50% in rel-
ative efﬁcacy and safety had no substantial impact on
the results. Furthermore, a meta-analysis of four sim-
ilarly designed studies in which fondaparinux was
compared with different dosing regimens of enoxa-
parin in different orthopedic populations showed con-
sistent efﬁcacy and safety results [43]. To maintain
external validity for the clinical outcome probabilities
used in this analysis a wide spectrum of randomized
controlled trials and cohort studies were assessed and
incorporated, reﬂecting contemporary clinical practice
in which patients do not routinely undergo venogra-
phy as in clinical trials. The assumptions were further
validated by an international advisory board. Further-
more, because the analysis only examines direct costs
related to the health-care system, incorporation of
indirect costs and patient focused issues such as quality
of life impairment would likely improve the cost-
effectiveness of fondaparinux.
In conclusion, this analysis demonstrates that in
patients undergoing hip fracture surgery, thrombo-
prophylaxis with fondaparinux, compared with enox-
aparin, is cost-saving with reduced clinical events
compared with enoxaparin. The results of the analysis,
in conjunction with the associated clinical trial results,
strengthen the claim of fondaparinux as the standard
of care for VTE prevention after hip fracture surgery.
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